skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Download this white paper, which looks at novel biologics in development for the treatment of uncontrolled, eosinophilic asthma and whether they can fulfill the promise of truly targeted therapies for one of the most prevalent respiratory diseases worldwide.

 

 

Novel Biologics for Asthma: Steps on the Long Road to Therapies for Uncontrolled Asthma

  

  • Overview of sponsors, molecular targets and current status of novel biologics targeting IL-5, IL-4 or IL-13 with development programs for asthma

     

  • Program trials and status for IL-5 and Th2 pathway antagonists

     

  • Key study design features including inclusion criteria, biomarkers and primary endpoints

     

  • Outcomes for efficacy trials of targeted biologics in asthma

     

  • Why stratification of the uncontrolled asthma population by specific biomarker levels could be crucial to reduce exacerbation rates and more

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: